دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
A role for HLA in mediating long-term multiple sclerosis outcomes?
Vilija G Jokubaitis
doi : 10.1177/13524585221139767
Volume 29 Issue 3, March 2023
Decentralised clinical trials in multiple sclerosis research
Afagh Garjani , Brandon Jun-Yu Liu, Christopher Martin Allen , Douglas David Gunzler, Stephen William Gerry, Sarah Marie Planchon , Roshan das Nair , Jeremy Chataway, Emma C Tallantyre , Daniel Ontaneda and Nikos Evangelou
doi : 10.1177/13524585221100401
Randomised controlled trials (RCTs) play an important role in multiple sclerosis (MS) research, ensuring that new interventions are safe and efficacious before their introduction into clinical practice. Trials have been evolving to improve the robustness of their designs and the efficiency of their conduct
Comparative effectiveness in multiple sclerosis: A methodological comparison
Izanne Roos , Ibrahima Diouf, Sifat Sharmin, Dana Horakova , Eva Kubala Havrdova, Francesco Patti , Vahid Shaygannejad , Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau , Marco Onofrj, Alessandra Lugaresi , Raed Alroughani , Alexandre Prat, Marc Girard, Pierre Duquette , Murat Terzi, Cavit Boz, Francois Grand’Maison, Patrizia Sola, Diana Ferraro, Pierre Grammond, Recai Turkoglu, Katherine Buzzard, Olga Skibina, Bassem Yamou, Ayse Altintas, Oliver Gerlach, Vincent van Pesch, Yolanda Blanco, Davide Maimone, Jeannette Lechner-Scott , Roberto Bergamaschi, Rana Karabudak, Chris McGuigan, Elisabetta Cartechini, Michael Barnett , Stella Hughes, Maria José Sa, Claudio Solaro, Cristina Ramo-Tello, Suzanne Hodgkinson, Daniele Spitaleri, Aysun Soysal, Thor Petersen, Franco Granella, Koen de Gans, Pamela McCombe, Radek Ampapa, Bart Van Wijmeersch, Anneke van der Walt , Helmut Butzkueven, Julie Prevost, Jose Luis Sanchez-Menoyo, Guy Laureys, Riadh Gouider, Tamara Castillo-Triviño , Orla Gray, Eduardo Aguera-Morales, Abdullah Al-Asmi, Cameron Shaw, Norma Deri, Talal Al-Harbi, Yara Fragoso , Tunde Csepany, Angel Perez Sempere, Irene Trevino-Frenk, Jan Schepel, Fraser Moore, Charles Malpas and Tomas Kalincik
doi : 10.1177/13524585231151394
In the absence of evidence from randomised controlled trials, observational data can be used to emulate clinical trials and guide clinical decisions. Observational studies are, however, susceptible to confounding and bias. Among the used techniques to reduce indication bias are propensity score matching and marginal structural models.
HLA-DRB1*1501 influences long-term disability progression and tissue damage on MRI in relapse-onset multiple sclerosis
Wallace J Brownlee, Carmen Tur, Andreea Manole, Arman Eshaghi, Ferran Prados, Katherine A Miszkiel, Claudia AM Gandini Wheeler-Kingshott, Henry Houlden and Olga Ciccarelli
doi : 10.1177/13524585221130941
Whether genetic factors influence the long-term course of multiple sclerosis (MS) is unresolved.
No seasonality in the risk of multiple sclerosis in an equatorial country: A case–control ecological study
Simón Cárdenas-Robledo , Paula González-Caicedo , Michael Steven Carvajal-Parra , Claudia Marcela GuÃo-Sánchez and Lorena López-Reyes
doi : 10.1177/13524585221130020
Multiple sclerosis risk has been shown to have seasonal variations that are more pronounced in higher latitudes. However, this phenomenon has not been adequately studied near the Equator.
Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis
Alberto Calvi* , Margareta A Clarke* , Ferran Prados, Declan Chard , Olga Ciccarelli, Manel Alberich, Deborah Pareto, Marta RodrÃguez Barranco, Jaume Sastre-Garriga , Carmen Tur , Alex Rovira and Frederik Barkhof
doi : 10.1177/13524585221141964
Magnetic resonance imaging (MRI) markers for chronic active lesions in MS include slowly expanding lesions (SELs) and paramagnetic rim lesions (PRLs).
Association of daily physical activity with brain volumes and cervical spinal cord areas in multiple sclerosis
Valerie J Block , Shuiting Cheng, Jeremy Juwono, Richard Cuneo, Gina Kirkish, Amber M Alexander, Mahir Khan , Amit Akula, Eduardo Caverzasi, Nico Papinutto, William A Stern *, Mark J Pletcher, Gregory M Marcus, Jeffrey E Olgin, Stephen L Hauser , Jeffrey M Gelfand, Riley Bove , Bruce AC Cree†and Roland G Henry
doi : 10.1177/13524585221143726
Remote activity monitoring has the potential to evaluate real-world, motor function, and disability at home. The relationships of daily physical activity with spinal cord white matter and gray matter (GM) areas, multiple sclerosis (MS) disability and leg function, are unknown.
Association of paramagnetic rim lesions and retinal layer thickness in patients with multiple sclerosis
Nik Krajnc , Assunta Dal-Bianco, Fritz Leutmezer, Gregor Kasprian, Berthold Pemp, Barbara Kornek, Thomas Berger , Paulus Stefan Rommer , Simon Hametner, Hans Lassmann and Gabriel Bsteh
doi : 10.1177/13524585221138486
Paramagnetic rim lesions (PRLs) are chronic active lesions associated with a more severe disease course in multiple sclerosis (MS). Retinal layer thinning measured by optical coherence tomography (OCT) is a biomarker of neuroaxonal damage associated with disability progression in MS.
Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial
Jens Kuhle, Tanuja Chitnis , Brenda Banwell, Marc Tardieu, Douglas L Arnold , Andreea M Rawlings, Svend S Geertsen, Alex L Lublin, Stephane Saubadu, Philippe Truffinet and Ludwig Kappos
doi : 10.1177/13524585221144742
The phase 3 TERIKIDS study demonstrated efficacy and manageable safety for teriflunomide versus placebo in children with relapsing multiple sclerosis (RMS).
Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus
Priyanka Iyer, Kate Wiles, Azza Ismail, Surabhi Nanda, Katy Murray, Stella Hughes, Helen L Ford , Owen R Pearson , Sarah White, Nicola Bonham, Natasha Hoyle, James Witts, Rod Middleton , Peter A Brex, David Rog and Ruth Dobson
doi : 10.1177/13524585221148094
Multiple sclerosis (MS) is frequently diagnosed in people of reproductive age, many of whom will become pregnant following diagnosis. Although many women report an improvement in symptoms and relapses during pregnancy, symptoms such as fatigue and spasticity are commonly reported and can worsen. Prescribing medications during pregnancy and breastfeeding presents unique challenges and guidance on the use of symptomatic therapies is limited.
The Canadian Multiple Sclerosis Pregnancy Study: First-trimester miscarriages in women with multiple sclerosis
Dessa Sadovnick , Maria Criscuoli, Irene Yee, Robert Carruthers , Alice Schabas, Virginia Devonshire and Penelope Smyth
doi : 10.1177/13524585221146270
There is increasing need for evidence-based data on reproduction for women with multiple sclerosis (MS). First-trimester (first 13 weeks) miscarriages are relatively common in the general population. It is therefore important to have information on the frequency with which this occurs in women with MS.
Primary results of a phase-III, randomized controlled trial of the Behavioral Intervention for increasing Physical Activity in Multiple Sclerosis project
Robert W Motl , Ariel Kidwell-Chandler , Brian M Sandroff , Lara A Pilutti , Gary R Cutter , Roberto Aldunate and Rachel E Bollaert
doi : 10.1177/13524585221146430
We undertook a phase-III, randomized controlled trial (RCT) that examined the effectiveness of a behavioral intervention based on social cognitive theory (SCT) and delivered through the Internet using e-learning approaches for immediate and sustained increases in physical activity among persons with multiple sclerosis (MS).
The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial
Robert J Fox , Tommi Tervonen , Andrea Phillips-Beyer, Tatiana Sidorenko, Neli Boyanova, Anne Brooks, Brian Hennessy, Carol Jamieson and Bennett Levitan
doi : 10.1177/13524585221140270
In the OPTIMUM trial in patients with relapsing MS, treatment differences in annualized relapse rate (ARR, 0.088) and change in fatigue at week 108 (3.57 points, measured using the Fatigue Symptoms and Impacts Questionnaire–Relapsing Multiple Sclerosis, symptom domain (FSIQ-RMS-S)) favored ponesimod over teriflunomide. However, the importance of the fatigue outcome to patients was unclear.
Pathways between multiple sclerosis, sleep disorders, and cognitive function: Longitudinal findings from The Nurses’ Health Study
Tiffany J Braley , Monica M Shieu, Afsara B. Zaheed and Galit Levi Dunietz
doi : 10.1177/13524585221144215
The potential mediating and moderating effects of sleep disorders on cognitive outcomes in multiple sclerosis (MS) have been insufficiently studied.
Family health conditions and parental occupational status modify the relationship between pediatric-onset multiple sclerosis and parental health-related quality of life
Julia O’Mahony , Brenda Banwell, Audrey Laporte, Adalsteinn Brown, Lady Bolongaita, Amit Bar-Or, E Ann Yeh and Ruth Ann Marrie ; On behalf of the Canadian Pediatric Demyelinating Disease Network
doi : 10.1177/13524585221144413
The health-related quality of life (HRQoL) of children with multiple sclerosis (MS) is mediated by the HRQoL of their parents. Understanding factors that modify the relationship between the child’s MS diagnosis and parental HRQoL would inform interventions to improve the HRQoL of both parents and children living with MS.
Fingerprick blood samples to measure serum natalizumab concentrations
Alyssa A Toorop* , Maurice Steenhuis*, Floris C Loeff, Suzanne S Weijers, Joep Killestein, Theo Rispens and Zoé LE van Kempen
doi : 10.1177/13524585221136448
Natalizumab via subcutaneous administration was recently approved for patients with multiple sclerosis.
Cladribine and pregnancy in women with multiple sclerosis: The first cohort study
Karen Dost-Kovalsky, Sandra Thiel, Andrea I Ciplea, Ralf Gold and Kerstin Hellwig
doi : 10.1177/13524585221131486
The aim of this study was to investigate the effects of cladribine use, in the last 6 months prior (56.4%) to or after (43.6%) the last menstrual period in a population of women with multiple sclerosis, on pregnancy outcomes and relapse rate during pregnancy and postpartum.
Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis
Floriane Calocer , Huah Shin Ng , Feng Zhu, Yinshan Zhao, Olivier Dejardin, Emmanuelle Leray, Gilles Defer, Charity Evans, John D Fisk, Ruth Ann Marrie and Helen Tremlett
doi : 10.1177/13524585221129963
The relationship between socioeconomic status (SES) and mortality among persons with multiple sclerosis (PwMS) is poorly understood.
Neurologic disease activity in people with multiple sclerosis treated with immune checkpoint inhibitors
Sarah E Conway , Danielle Kei A Pua, Kathryn B Holroyd, Kristin Galetta and Shamik Bhattacharyya
doi : 10.1177/13524585221117949
There is concern that immune checkpoint inhibitors (ICPIs) can provoke relapses in people with multiple sclerosis (pwMS).
Evaluating the central vein sign in paediatric-onset multiple sclerosis: A case series study
Vincenzo Daniele Boccia* , Caterina Lapucci*, Maria Cellerino, Francesco Tazza , Andrea Rossi, Simona Schiavi , Maria Margherita Mancardi and Matilde Inglese
doi : 10.1177/13524585221142319
The central vein sign (CVS) has been proposed as a biomarker of multiple sclerosis (MS). In adult-onset MS (AOMS), 40%-threshold of CVS positive (+) lesions demonstrated high accuracy for MS diagnosis. However, CVS+ lesions’ performance has not been characterized in paediatric-onset (POMS) yet.
Is the central vein sign a useful diagnostic marker for paediatric-onset multiple sclerosis?
Omar Abdel-Mannan and Olga Ciccarelli
Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study
Federica Magnè1,*, Maria Cellerino2,*, Elisa Balletto 1, Kenda Aluan2 , Matilde Inglese 2,3, Malgorzata Mikulska1,2,3,4 and Matteo Bassetti
Confronting a misnomer about the SDMT: A David and Goliath story
Victoria M Leavitt
Construct validity of the symbol-digit modalities test
Ralph HB Benedict1 and Alan Smerbeck
Reliable change indices for cognitive assessment of patients with multiple sclerosis
Emilio Portaccio1 and Maria Pia Amato
